Propella develops innovative, best-in-class therapeutics with an eye toward mitigated development risk. We use proven science and development insight to produce products that are smarter, safer and more effective.
We are a privately held development-stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action. Our lead product candidate, PRL-02, has completed nonclinical Investigational New Drug (IND)-enabling studies for metastatic prostate cancer and will began clinical development in the first half of 2021. Topical CGS-200-5 is being developed for the management of knee pain due to osteoarthritis (OA) and is Phase 3 ready, having successfully completed a predictive Phase 2 study.
Both PRL-02 and CGS-200-5 product candidates are covered by issued US patents that are wholly owned by Propella.